FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry and is an antibody comprising a heavy chain and a light chain capable of specifically binding to programmed cell death protein 1 (PD-1). Invention also relates to a pharmaceutical composition for the treatment or prophylaxis of PD-L1-positive cancer or a PD-L1-positive infectious disease comprising the claimed antibody and a pharmaceutically acceptable carrier.
EFFECT: invention can effectively treat or prevent PD-L1-positive cancer or PD-L1-positive infectious diseases in a patient in need thereof.
12 cl, 8 dwg, 3 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-1 ANTIBODIES | 2015 |
|
RU2711141C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| ANTIBODIES TO PD-1 AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2701797C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| PD-1 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2722451C1 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
